drugset / Trial / NCT06100913
Immunology of Ebola Vaccine
Phase 2
Active not recruiting
30 enrolled
Emory University
Merck Sharp & Dohme LLC · collabWashington University School of Medicine · collab
Non-randomizedParallel-groupOpen-labelBasic science
Summary
In this study 30 healthy adult participants will receive a single dose of an Ebola vaccine. Blood samples, fine needle aspirates, core biopsies, and bone marrow aspirates will be collected prior to and following vaccination to assess immune responses in the blood, lymph nodes, and bone marrow over multiple time points.
Timeline
- Start
- 2024-08-06
- Primary completion
- 2027-08-31
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ervebo | Vaccine | 1 ml | Intramuscular |